Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is used to suppress GvHD in patients undergoing hematopoietic stem cell transplantation (HCT). The purpose of this study was to construct a population pharmacokinetic and pharmacodynamic model in HCT patients for individualized MPA therapy. Blood samples were obtained from 49 HCT patients after starting MMF therapy. Population pharmacokinetic and pharmacodynamic parameters were obtained using the program NONMEM. MPA was described via a one-compartment model with a first-order elimination, and 30.9% of MPA glucuronide (MPAG) was found in the enterohepatic circulation. Inosine-5′-monophosphate dehydrogenase (IMPDH) activity was modeled as a maximal inhibitory model with a half-maximal inhibitory concentration (IC 50 ) of 3.59 μg/mL against MPA concentrations. Simulations based on the obtained pharmacokinetic and pharmacodynamic parameters revealed that decreased creatinine clearance increases the MPAG concentration followed by an increased MPA concentration; therefore, IMPDH activity decreases. Diarrhea decreases the enterohepatic circulation of MPAG and consequently reduces MPA concentration. The IC 50 for MPA exhibited a positive association with C-reactive protein. Dosage adjustment based on plasma MPA concentration is required especially for patients with renal dysfunction and/or diarrhea.
INTRODUCTION
Mycophenolate mofetil (MMF) is clinically used to suppress GvHD in patients undergoing hematopoietic stem cell transplantation (HCT) and acute rejection after solid organ transplantation. 1, 2 Mycophenolic acid (MPA), an active form of MMF, is metabolized by glucuronosyltransferases in the liver. MPA glucuronide (MPAG) and MPA acyl glucuronide (AcMPAG) are primarily produced by UGT1A9 and 2B7, respectively. 3 While MPAG is an inactive metabolite, AcMPAG exhibits pharmacological activity in vitro and is potentially responsible for the toxicity of MPA. 4 The majority of MPA metabolites are eliminated via the urine and partial elimination also occurs in the bile mediated by multidrug resistance-associated protein 2 (MRP2) followed by the enterohepatic recirculation. 5 The pharmacokinetics (PK) of MPA exhibit a large inter-and intra-individual variability, and it is recommended that the area under the concentration-time curve (AUC) of MPA be monitored for individualized therapy in solid organ transplant recipients. 6, 7 Recently, Arai et al. 8 proposed that MPA drug monitoring was necessary for the effective prophylaxis of acute GvHD undergoing cord blood stem cell transplantation (CBT). However, information regarding the optimal dose of MMF or the target range for MPA concentrations in HCT patients is limited. 9 MPA selectively inhibits inosine-5′-monophosphate dehydrogenase (IMPDH) and suppresses the proliferation of B and T lymphocytes. 10 IMPDH exists as two isoforms derived from different genes, 11, 12 and recombinant proteins of IMPDH2 is 4.8-fold more sensitive to MPA than IMPDH1. 13 The area under the effect curve (AUEC) of IMPDH activity on day 21 after HCT was reportedly associated with both non-relapse and overall mortality.
14 Therefore, the measurement of IMPDH activity in peripheral blood mononuclear cells (PBMCs) in addition to monitoring the AUC of MPA is considered to be an effective predictor of the clinical outcome of MPA therapy.
The PK of MPA is influenced by serum albumin, renal dysfunction, total bilirubin, age, co-administration with cyclosporine and dose. [15] [16] [17] [18] [19] In addition, the incidence of acute rejection in the first year post transplantation was significantly lower in carriers of SNPs for IMPDH1 − 106 G4A and 125 G4A compared with the respective wild-type individuals. 20 The SNP for IMPDH2 3757 T4C was associated with a significantly higher IMPDH activity following the MMF intake, despite of no difference in the MPA exposure between the groups. 21 The SNP for MRP2 − 24 C4T was associated with a significantly higher dose-corrected MPA trough levels at later time points after transplantation. 22 The SNP for UGT2B7 − 842G4A resulted in a significantly higher AUC of AcMPAG at 1 and 3 months post transplantation in patients with renal transplantation. 23 In this study, the effects of the patient characteristics including previously proven genetic polymorphisms were examined using a population PK and pharmacodynamics (PD) analysis. Effects of covariates were quantitatively evaluated by the simulation to examine the clinical significance of these covariates.
SUBJECTS AND METHODS

Study design
A total of 49 adult Japanese HCT patients between March 2013 and August 2016 were included in the study. Acute GvHD prophylaxis comprised tacrolimus (Prograf, Astellas Pharma Inc., Tokyo, Japan) and MMF (Cellcept, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) in CBT, plus short-term methotrexate (Methotrexate, Pfizer Japan Inc., Tokyo, Japan) in bone marrow transplant (BMT) or peripheral blood stem cell transplantation (PBT). MMF was orally administered at 10 mg/kg every 8 h (30 mg/kg per day), and was initiated on day − 1 after CBT or on day-7 after BMT and PBT, except in one patient administered 15 mg/kg every 12 h. No potentially interacting drugs including cyclosporine or foods with MPA were co-administered.
Pre-transplant recipient DNA was used to determine UGT2B7 − 842C4T (rs7439366) and MRP2 − 24C4T (rs717620) genotypes. Approximately 5 weeks after MMF administration commenced, post-transplant donor DNA as well as pre-transplant recipient DNA were used to determine IMPDH1 − 106G4A (rs2278294), IMPDH1 125G4A (rs2278293) and IMPDH2 3757T4C (rs11706052) genotypes. Blood samples were collected immediately before 1, 2, 4 and 8 h after the first and third weeks after MMF administration commenced, plus blood sampling at 12 h after MMF administration in one patient administered 15 mg/kg every 12 h. This clinical study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine and Kyoto University Hospital. Written informed consent was obtained from all patients included in the study.
Analytical methods
Total plasma concentrations of MPA, MPAG and AcMPAG were analyzed using LC-MS/MS according to the previously reported method. 24 The lower limits of quantification (LLOQ) were 0.05, 0.2 and 0.02 μg/mL for MPA, MPAG, and AcMPAG, respectively. PBMC samples were used to measure the IMPDH activity according to the previous method. 24 The IMPDH activity was calculated based on the XMP produced, which was normalized to the intracellular AMP. The LLOQ were 50 nM for both XMP and AMP. The data for AMP under the LLOQ were excluded from the analysis due to extremely low white blood cell counts after the transplantation.
Population PK/PD analysis A population PK analysis was conducted using NONMEM. The overview of the basic PK/PD model for MPA is shown in Figure 1 . Since only the oral data were available, the relative bioavailability (F) of MPA was assumed to be 1. The model was parameterized using clearances for MPA, MPAG and AcMPAG (CL MPA, CL MPAG and CL AcMPAG ), as well as the volume of distribution for MPA, MPAG, and AcMPAG (V MPA, V MPAG and V AcMPAG ). It was assumed that MPA was metabolized to MPAG and AcMPAG by a firstorder process, in which 99 and 1% of MPA was converted to MPAG and AcMPAG, respectively, because the ratio of AUC 0-8 for MPAG to AcMPAG was approximately 99:1 in this study. The enterohepatic circulation (EHC) was tested as a first-order process (K EHC ) from the central compartment of each metabolite to the gastrointestinal tract. For the comparison, two-compartment model with EHC, and the lag-time and the transit compartment models in the absorption process were tested. 25 Additionally, EHC modeling by presuming a hypothetical gall bladder compartment was tested. 26, 27 Interindividual and interoccasion variability (IIV and IOV) in the PK/PD parameters were modeled using an exponential error model. 28 The estimation for the IOV was as follows: occasions 1 and 2 pertained to 1 and 3 weeks after MMF administration commenced, respectively. The influence of each covariate on the population mean parameters was evaluated by the stepwise forward inclusion and backward elimination method, and significance levels were 1 and 0.1% (6.63 and 10.8 with freedom of 1 assuming a Χ 2 distribution), respectively. The tested covariates for the PK parameters included body weight, gender, stem cell source, age, aspartate aminotransferase, serum albumin, total bilirubin, creatinine clearance (CL CR ), dose of MMF, diarrhea and investigated genotypes for MRP2 and UGT2B7 of recipient. Diarrhea was defined as the occurrence of loose, muddy or watery stool, or more than five times per a day of fecal frequency in case of not recording the fecal condition.
Continuous variables were normalized by each population median using the following power function model:
where θ i is the individual model-predicted PK parameter (for example, CL MPA ) for an individual with covariate value of COV i . θ pop represents the population mean for the parameter θ, COV med represents the population median of the covariate, and θ cov represents the covariate effect. For dichotomous variables, the value of COV i is typically set to 0 for the normal classification and 1 for the other classification in each individual as follows:
After the final population PK model was obtained, the relationship between the MPA concentrations and IMPDH activity was explored graphically and modeled using a direct sigmoid inhibitory maximum effect model as follows:
where E 0 , IC 50,MPA and γ represent baseline of IMPDH activity, half-maximal inhibitory MPA concentration, and the Hill coefficient to be estimated, 29 and C MPA represents the MPA concentration. To investigate the effect of the AcMPAG concentration on IMPDH activity, an additional inhibitory effect model was tested. 30 The tested covariates for the PD parameters included the stem cell source, reduced-intensity conditioning, gender, age, serum albumin, C-reactive protein (CRP) and investigated genotypes (IMPDH1 and 2) of donor or recipient. In the value of CRP was under the LLOQ (o 0.2 mg/mL), this value was converted to 0.1 due to the difficulty of the calculation. Goodness-of-fit and prediction-corrected visual predictive check plots were used for internal validation. 31 For predictioncorrected visual predictive check plots, the final PK/PD model was used to simulate the original data sets at 1000 times compared with the observed data.
Simulation study
The effects of statistically significant covariates on the PK/PD of MPA were evaluated by the simulation using the final population parameters. The dose was fixed to 500 mg every 8 h for all simulations. In the simulation for the effect of each covariate, other covariates were fixed to the median value of each covariate and without diarrhea. The AUC 0-8 or AUEC 0-8 were calculated using the linear trapezoidal method.
RESULTS
Patient characteristics
The patient characteristics and the distribution of each genotype before and 5 weeks after the transplantation are summarized in Table 1 . All of the observed genotype distributions were consistent with Hardy-Weinberg equilibrium.
Population PK modeling In total, 522 concentration data sets for MPA, MPAG and AcMPAG, respectively, were analyzed. Five samples with MPA concentrations under the LLOQ were replaced with half of the LLOQ, 32 and included in the analysis. Two-compartment model improved the model fitting compared with one-compartment model without EHC. However, after an inclusion of EHC process, two-compartment model did not improve the model fitting compared with one-compartment model (ΔOBJ = − 8.12), and a terminal elimination rate constant was not correctly estimated. Therefore, the PK of MPA was finally described by one-compartment model with first-order absorption and elimination, and was affected by the EHC of MPAG. An inclusion of the absorption lag-time did not improve the model fitting. Transit compartment model was not adopted owing to the high computational intensity required, although the model fit was significantly improved. Although the inclusion of EHC of AcMPAG in the model brought a statistically significant model improvement, CL AcMPAG was not correctly estimated. Therefore, the model including the EHC of only MPAG was selected. EHC modeling by presuming a hypothetical gall bladder compartment did not improve the model fitting compared with first-order EHC model. The simultaneous inclusion of IOVs for Ka, F, K EHC , CL MPAG , and CL AcMPAG significantly improved the model fitting (ΔOBJ = − 721). The final PK parameters and its relative standard error (RSE) are presented in Table 2 . Figure 2 shows the Abbreviations: AST = aspartate aminotransferase; BMT = bone marrow stem cell transplantation; CBT = cord blood transplantation; IMPDH = inosine-5′-monophosphate dehydrogenase; MAC = myeloablative conditioning; MMF = mycophenolate mofetil; MRP = multidrug resistanceassociated protein; PBT = peripheral blood stem cell transplantation; RIC = reduced-intesity conditioning; UGT = UDP-glucuronosyltransferase.
a Genotypes in two patients were unknown because one patient underwent the second stem cell transplantation and the other patient was defective in collecting recipient's DNA. Abbreviations: ALB = serum albumin concentration; CL AcMPAG = clearance of AcMPAG; CL CR = creatinine clearance; CL MPA = clearance of MPA; CL MPAG = clearance of MPAG; CRP = C-reactive protein; F = relative bioavailability; E 0 = baseline of IMPDH activity; IC 50 = half-maximal inhibitory concentration; Ka = first-order absorption rate constant; K EHC = first-order rate constant of enterohepatic circulation; V AcMPAG = volume of distribution of AcMPAG; V MPA = volume of distribution of MPA; V MPAG = volume of distribution of MPAG. The final pharmacokinetic and pharmacodynamic models were described as follows: CL MPA ¼ y CL;MPA ð interoccasional parameters for 1 and 3 weeks after MMF administration commenced. After the evaluation of each covariate, the serum albumin revealed a significant negative association with CL MPA and V MPA . CL CR exhibited a significant positive relationship with both CL MPAG and CL AcMPAG , and K EHC in the patients showing diarrhea was 0.375-fold lower than that without diarrhea (Table 2 ). An inclusion of IIV was tested for all the MPA PK parameters and an exclusion of IIV was tested after inclusion of IOV. After all, IIVs on V MPA and F were retained in the final model, and shrinkage values of them were 27.6% and 16.8%, respectively. The ratio for the EHC of MPAG was estimated to be 30.9% (EHC(%) = K EHC /(K EHC +CL MPAG / V MPAG ) × 100) in patients with CL CR of 112 mL/min without diarrhea. PD modeling A total of 460 IMPDH activity data sets from 49 patients were used for the PD model building following the PK modeling process. The 62 IMPDH activity data were excluded due to AMP under the LLOQ. The IMPDH activity was described with the inhibitory E max model using the MPA concentrations. The Hill coefficient was fixed to 1 by the statistical selection (ΔOBJ = − 3.00). The additive inhibitory effect model for AcMPAG did not significantly improve the model fitting. An inclusion of IOV on E 0 significantly improved the model fitting (ΔOBJ = − 200). The value of IC 50 for MPA revealed a positive association with CRP (ΔOBJ = − 11.4). No polymorphisms were identified as significant covariates in the PK/ PD model. The final PD parameters with RSE are shown in Table 2 . The IIV for IC 50 was 81.2%, and its shrinkage was 29.7%. The goodness-of-fit and prediction-corrected visual predictive check demonstrated that the population PK/PD model accurately predicted the observed MPA and its metabolites concentrations, as well as IMPDH activity (Figures 3 and 4) .
Simulation study A total of 1,000 data sets in each group were simulated under the several renal functions with or without diarrhea ( Figure 5 ). The AUC 0-8 of MPAG and AcMPAG significantly increased according to the decreased CL CR compared with those for 120 mL/min. The AUC 0-8 of MPA also significantly increased according to the decreased CL CR . The AUEC 0-8 of IMPDH significantly decreased from 339 to 215 μmol h/sec·mol AMP − 1 with a decrease in CL CR from 120 to 10 mL/min; however, a large interindividual variability was noted. In addition, the diarrhea significantly decreased the AUC 0-8 of both MPA and AcMPAG in every CL CR , but did not affect the AUC 0-8 of MPAG. The AUEC 0-8 of IMPDH with diarrhea was significantly higher than that without diarrhea in the case of CL CR under 60 mL/min.
The AUC 0-8 of MPA significantly decreased with a reduction in serum albumin, although the AUEC 0-8 of IMPDH did not significantly change (Figure 6 ). At a MPA concentration of 3.59 μg/mL, which is equal to the population mean of IC 50 in the case of CRP of 1.2 mg/dL, the IMPDH activity is 1.34-fold higher in patients with CRP of 10 mg/dL, compared with that for CRP of 1.2 mg/dL. The AUEC 0-8 of IMPDH also significantly increases as the CRP rises.
DISCUSSION
Patients undergoing HCT generally have intestinal mucosal damage due to a myeloablative or reduced-intensity conditioning regimen prior to HCT. 33 Indeed, MPA concentrations in HCT patients are generally lower than those of organ transplant patients despite an equivalent dose of MMF. 34 In addition, leukopenia and co-administered antibiotics induce the destruction of intestinal flora, leading to diarrhea. The diarrhea decreased the reabsorption of MPA in the gastrointestinal tract, and consequently decreased the MPA concentration. In this study, IMPDH activity in CL CR under 60 mL/min with diarrhea was significantly higher compared to those in the same CL CR without diarrhea in the same MPA dosing, secondary to the PK changes. In the early phase after transplantation, HCT patients suffer from renal impairment due to thrombotic microangiopathy, which is an adverse effect caused by calcineurin inhibitors and high-dose chemotherapy. 35 Since MPA metabolites are excreted into the urine, the clearance of MPA metabolites have been reported to decrease in association with lower renal function. 14, 36 In the simulation using the final PK/PD parameters, MPA concentration will be increased with a decreased CL CR , due to the enhanced EHC of MPAG. Moreover, the IMPDH activity in CL CR under 30 mL/min was significantly lower than that in 120 mL/min. Therefore, particular attention regarding extra-immunosuppression in response to MPA is needed for patients with severe renal dysfunction.
The target range of MPA exposure may be influenced by changes in serum albumin, since the free fraction of MPA was 1-2%. 37 In the PD analysis, we speculated that the serum albumin had a significant effect on the IC 50 value of MPA due to the changed unbound fraction of MPA; however, we were unable to conclusively demonstrate this effect due to a large inter-and intra-individual variability in IMPDH activity. Therefore, changes in the serum albumin in clinical situations might not have a significant effect on IMPDH activity, although it can affect the PK of MPA.
Interestingly, CRP exhibited a positive association with the IC 50 for MPA. Patients undergoing HCT suffered from various symptoms caused by an infection and/or the excessive production of inflammatory cytokines on the days around the engraftment. 38, 39 Indeed, the median of CRP in 1 week after starting the MMF therapy (3.0 mg/dL) was significantly higher than that in 3 weeks after the therapy (0.8 mg/dL). Moreover, IMPDH1 is constitutively expressed in normal leukocytes, whereas IMPDH2 is upregulated in neoplastic and replicating cells. 40, 41 These findings suggest the reasons why CRP exhibited a positive association with the IC 50 for MPA. Whether the elevated CRP value reflects infection or excessive production of inflammatory cytokines remains to be examined.
The simultaneous inclusion of IIVs and IOVs for PK/PD parameters significantly improved the model fitting. HCT patients have single or multiple damages due to the conditioning regimen, infection or excessive production of inflammatory cytokines. 33, 38, 39, 42 In addition, the recovery rate of organic and hematopoietic functions following HCT showed a large variability. Therefore, the IIV and IOV in the PK/PD of MPA in HCT patients should be large.
The present study included some limitations. The PK of MPA is usually expressed as two-compartment model, and/or sometimes includes more sophisticated models. 26, 27 In this study, the model fitting was not improved by using any sophisticated models. The examined model largely depends on the experimental design, and we would like to pick up clinical significant covariates on the PK of MPA in a routine clinical care as shown in the previous our study. 8 Additionally, although our population size was modest, the estimated parameters, such as the ratio of EHC of MPAG or the IC 50 for MPA, were similar to those of previous reports. 14 Therefore, the constructed PK/PD model for MPA was considered to be appropriate. The effects of covariates extracted in the present study should be examined by two-compartment model using more rich sampling data in a future.
In conclusion, we successfully constructed a population PK/PD model of MPA in patients undergoing HCT. Renal dysfunction, diarrhea, and CRP are clinically significant factors affecting the PD of MPA in the same dosing regimen. Dosage adjustment based on plasma MPA concentration is required especially for patients with renal dysfunction and/or diarrhea.
